NIH has released four new SBIR/STTR solicitations (first deadline for all solicitations is September 8, 2026): Parent SBIR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track SBIR awards Parent STTR (Clinical Trial Optional) accepts Phase I, Phase II, Direct-to-Phase II, and Fast-Track STTR awards SBIR Phase IIB Strategic Breakthrough Award (Clinical Trial Optional) accepts Phase IIB Strategic Breakthrough SBIR awards (for Phase II awardees) SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Clinical Trial Optional) accepts CRP awards (for Phase II awardees) Updated summaries of the research interests, budget waiver topics, and award mechanisms supported by individual Institutes and Centers (ICs) are now housed on the Small Business Funding Considerations and Contacts webpage
Your PlexusDx provider will review your full medication list and any personal or family history of serotonin-related complications to ensure safe treatment selection
Your provider will likely draw your attention to some potential mild side effects, such as nausea, vomiting, diarrhea, dizziness, headaches, and loss of appetite
Your BodyLogicMD provider will consider your medical history, current health status, and treatment goals when determining whether GLP-1 shots are right for you
We explained our situation and asked if Dr